Cargando…
Response to mRNA vaccination for COVID-19 among patients with multiple myeloma
Multiple myeloma (MM) patients are at higher risk for severe COVID-19. Their mRNA vaccination response against SARS-CoV-2 is unknown. Thus, we analyzed responses to mRNA vaccination against COVID-19 among these patients. Using an ELISA-based assay that detects IgG antibodies to SARS-CoV-2 spike prot...
Autores principales: | Stampfer, Samuel D., Goldwater, Marissa-Skye, Jew, Scott, Bujarski, Sean, Regidor, Bernard, Daniely, David, Chen, Haiming, Xu, Ning, Li, Mingjie, Green, Tracy, Fung, Eddie, Aquino, Elias, Swift, Regina, Eshaghian, Shahrooz, Preugschat, Kurt, Feinstein, Aaron J., Spektor, Tanya M., Berenson, James R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320411/ https://www.ncbi.nlm.nih.gov/pubmed/34326466 http://dx.doi.org/10.1038/s41375-021-01354-7 |
Ejemplares similares
-
Loss of anti‐spike antibodies following mRNA vaccination for COVID‐19 among patients with multiple myeloma
por: Stampfer, Samuel D., et al.
Publicado: (2023) -
Sars-Cov-2 Antibody Decay Monitoring in mRNA Vaccinated Multiple Myeloma Patients
por: Stampfer, Samuel D., et al.
Publicado: (2021) -
Severe breakthrough COVID-19 with a heavily mutated variant in a multiple myeloma patient 10 weeks after vaccination
por: Stampfer, Samuel D., et al.
Publicado: (2022) -
Third dose of an mRNA COVID-19 vaccine for patients with multiple myeloma
por: Goldwater, Marissa-Skye, et al.
Publicado: (2023) -
Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients
por: Ghermezi, Michael, et al.
Publicado: (2017)